US2019255041A1PendingUtilityA1
Compositions and methods for treating ezh2-mediated cancer
Assignee: ICAHN SCHOOL MED MOUNT SINAIPriority: Oct 28, 2016Filed: Oct 27, 2017Published: Aug 22, 2019
Est. expiryOct 28, 2036(~10.3 yrs left)· nominal 20-yr term from priority
A61K 47/55A61K 47/545A61P 35/00A61P 35/02A61P 43/00C07D 405/12C07D 401/14C07D 405/14C07D 417/14A61K 31/496A61K 31/444C07D 401/04A61K 31/4545
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods for designing bivalent compounds which selectively degrade/disrupt EZH2 and compositions and methods of using such degraders/disruptors to treat EZH2-mediated cancer are provided.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A bivalent compound comprising an enhancer of zeste homologue 2 (EZH2) ligand conjugated to a degradation/disruption tag.
2 . The bivalent compound of claim 1 , wherein the EZH2 ligand is an EZH2 inhibitor.
3 . The bivalent compound of claim 2 , wherein the EZH2 ligand is selected from the group consisting of UNC1999, EPZ005687, EPZ-6438, GSK126, EI1, CPI-1205, GSK343, CPI-360, EPZ011989, compound 24, compound 3, compound 31, ZLD1039, PF-06821497, JQEZ5, and analogs thereof.
4 . The bivalent compound of any one of claims 1 to 3 , wherein the degradation/disruption tag is selected from the group consisting of adamantane, 1-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonane, pomalidomide, thalidomide, lenalidomide, VHL-1, and analogs thereof.
5 . The bivalent compound of any one of claims 1 to 4 , wherein the degradation/disruption tag binds to a ubiquitin ligase or mimics EZH2 protein misfolding.
6 . The bivalent compound of claim 5 , wherein the ubiquitin ligase is an E3 ligase.
7 . The bivalent compound of claim 6 , wherein the E3 ligase is selected from the group consisting of cereblon E3 ligase and VHL E3 ligase.
8 . The bivalent compound of claim 5 , wherein the degradation/disruption tag that mimics EZH2 protein misfolding comprises a hydrophobic group.
9 . The bivalent compound of any one of claims 1 - 8 , wherein the EZH2 ligand is conjugated to the degradation/disruption tag through a linker.
10 . The bivalent compound of claim 9 , wherein the linker comprises an acyclic or cyclic saturated or unsaturated carbon, ethylene glycol, amide, amino, ether, or carbonyl containing group.
11 . The bivalent compound of claim 9 or 10 , wherein the linker is selected from the group consisting of:
12 . The bivalent compound of claim 9 or 10 , wherein the linker is:
wherein R is independently —CH 2 —; —CF 2 —; —CH(C 1-3 alkyl)-; —C(C 1-3 alkyl)(C 1-3 alkyl)-;
—CH═CH—; —C(C 1-3 alkyl)═C(C 1-3 alkyl)-; —C≡C—; —O—; —NH—; —N(C 1-3 alkyl)-;
—C(O)NH—; —C(O)N(C 1-3 alkyl)-; or a 3-13 membered ring, a fused ring, a bridged ring, or a spiro ring with or without one or more heteroatoms selected from the group consisting of —NH—, —N(C 1-3 alkyl)-, and —O—;
X and Y are independently O or H 2 ; and
m and n are independently 0-15.
13 . The bivalent compound of claim 12 , wherein R is selected from the group consisting of:
wherein X′ and Y′ are independently N or CH, and m, n, o, and p are independently 0-5;
or the group consisting of:
wherein A, B, C, and D are independently CH, C(C 1-3 alkyl), or N, and
wherein A, B, C, D, and E are independently CH, C(C 1-3 alkyl), N, NH, N(C 1-3 alkyl), O, or S.
14 . The bivalent compound of any of claims 1 - 13 , wherein the bivalent compound is selected from the group consisting of AM16-10A, AM16-11A, AM16-37A, AM16-38A, XY019-43, XY019-44, XY019-079, XY019-080, AM16-91A, AM16-92A, AM16-93A, AM16-97A, AM16-100A, AM16-101A, AM16-102A, AM16-105A, AM16-106A, XY012-120, AM29-21A, AM29-22A, AM29-32A, AM29-33A, AM16-103A, AM29-182A, AM29-55A, AM29-151A, AM29-152A, AM29-137A, AM29-153A, AM29-138A, AM29-154A, AM29-139A, AM29-155A, AM29-170A, AM29-156A, AM29-171A, AM29-157A, AM29-172A, AM29-173A, AM16-79A, AM29-177A, AM29-141A, AM29-178A, AM29-142A, AM29-179A, AM29-143A, AM29-180A, AM29-144A, AM29-145A, AM29-181A, AM41-16A, AM41-17A, AM41-18A, XY012-157, XF034-164A, XF034-165A, XF034-166A, XF034-167A, XF034-168A, XY019-041, XF034-169A, XF034-170A, XF034-171A, CZ40-10, CZ40-09, CZ40-11, XY019-077, XY019-083, XY019-084, XF034-172A, XF034-173A, XF034-174A, XF034-175A, XF034-176A, XF034-177A, YS36-48, YS36-49, YS36-50, YS36-51, YS36-52, YS36-53, YS36-54, YS36-55, YS36-56, YS36-57, YS36-58, YS36-59, XY028-086, CZ40-72, CZ40-73, CZ40-75, CZ40-149, CZ40-74, CZ40-131, AM41-36A, AM41-37A, AM41-39A, AM41-41A, AM41-38A, AM41-40A, XF042-84, XF042-85, XF042-95, XF042-132, XF042-86, XF042-94, XF042-89, XF042-90, XF042-93, XF042-133, XF042-91, and XF042-92.
15 . A bivalent compound selected from the group consisting of AM16-10A, AM16-11A, AM16-37A, AM16-38A, XY019-43, XY019-44, XY019-079, XY019-080, AM16-91A, AM16-92A, AM16-93A, AM16-97A, AM16-100A, AM16-101A, AM16-102A, AM16-105A, AM16-106A, XY012-120, AM29-21A, AM29-22A, AM29-32A, AM29-33A, AM16-103A, AM29-182A, AM29-55A, AM29-151A, AM29-152A, AM29-137A, AM29-153A, AM29-138A, AM29-154A, AM29-139A, AM29-155A, AM29-170A, AM29-156A, AM29-171A, AM29-157A, AM29-172A, AM29-173A, AM16-79A, AM29-177A, AM29-141A, AM29-178A, AM29-142A, AM29-179A, AM29-143A, AM29-180A, AM29-144A, AM29-145A, AM29-181A, AM41-16A, AM41-17A, AM41-18A, XY012-157, XF034-164A, XF034-165A, XF034-166A, XF034-167A, XF034-168A, XY019-041, XF034-169A, XF034-170A, XF034-171A, CZ40-10, CZ40-09, CZ40-11, XY019-077, XY019-083, XY019-084, XF034-172A, XF034-173A, XF034-174A, XF034-175A, XF034-176A, XF034-177A, YS36-48, YS36-49, YS36-50, YS36-51, YS36-52, YS36-53, YS36-54, YS36-55, YS36-56, YS36-57, YS36-58, YS36-59, XY028-086, CZ40-72, CZ40-73, CZ40-75, CZ40-149, CZ40-74, CZ40-131, AM41-36A, AM41-37A, AM41-39A, AM41-41A, AM41-38A, AM41-40A, XF042-84, XF042-85, XF042-95, XF042-132, XF042-86, XF042-94, XF042-89, XF042-90, XF042-93, XF042-133, XF042-91, and XF042-92.
16 . A method of treating an enhancer of zeste homologue 2 (EZH2)-mediated cancer, comprising administering to a subject in a subject in need thereof with an EZH2-mediated cancer a bivalent compound comprising an enhancer of zeste homologue 2 (EZH2) ligand conjugated to a degradation/disruption tag.
17 . The method of claim 16 , wherein the EZH2-mediated cancer overexpresses EZH2 relative to a wild-type tissue of the same species and tissue type.
18 . The method of claim 16 or 17 , wherein the EZH2-mediated cancer comprises hyper-trimethylated H3K27.
19 . The method of any of claims 16 - 18 , wherein the at least one bivalent compound is selected from the group consisting of AM16-10A, AM16-11A, AM16-37A, AM16-38A, XY019-43, XY019-44, XY019-079, XY019-080, AM16-91A, AM16-92A, AM16-93A, AM16-97A, AM16-100A, AM16-101A, AM16-102A, AM16-105A, AM16-106A, XY012-120, AM29-21A, AM29-22A, AM29-32A, AM29-33A, AM16-103A, AM29-182A, AM29-55A, AM29-151A, AM29-152A, AM29-137A, AM29-153A, AM29-138A, AM29-154A, AM29-139A, AM29-155A, AM29-170A, AM29-156A, AM29-171A, AM29-157A, AM29-172A, AM29-173A, AM16-79A, AM29-177A, AM29-141A, AM29-178A, AM29-142A, AM29-179A, AM29-143A, AM29-180A, AM29-144A, AM29-145A, AM29-181A, AM41-16A, AM41-17A, AM41-18A, XY012-157, XF034-164A, XF034-165A, XF034-166A, XF034-167A, XF034-168A, XY019-041, XF034-169A, XF034-170A, XF034-171A, CZ40-10, CZ40-09, CZ40-11, XY019-077, XY019-083, XY019-084, XF034-172A, XF034-173A, XF034-174A, XF034-175A, XF034-176A, XF034-177A, YS36-48, YS36-49, YS36-50, YS36-51, YS36-52, YS36-53, YS36-54, YS36-55, YS36-56, YS36-57, YS36-58, YS36-59, XY028-086, CZ40-72, CZ40-73, CZ40-75, CZ40-149, CZ40-74, CZ40-131, AM41-36A, AM41-37A, AM41-39A, AM41-41A, AM41-38A, AM41-40A, XF042-84, XF042-85, XF042-95, XF042-132, XF042-86, XF042-94, XF042-89, XF042-90, XF042-93, XF042-133, XF042-91, and XF042-92.
20 . The method of any of claims 16 - 19 , wherein the at least one bivalent compound is administered orally, parenterally, intradermally, subcutaneously, topically, or rectally.
21 . The method of any of claims 16 - 20 , further comprising treating the subject with one or more additional therapeutic regimens for treating cancer.
22 . The method of claim 21 , wherein the one or more additional therapeutic regimens are selected from the group consisting of surgery, chemotherapy, radiation therapy, hormone therapy, and immunotherapy.
23 . The method of any of claims 16 - 22 , wherein the EZH2-mediated cancer is selected from the group consisting of breast cancer, glioblastoma, prostate cancer, uterine cancer, ovarian cancer, pancreatic cancer, melanoma, renal cell carcinoma, bladder cancer, colorectal cancer, lymphoma, leukemia, malignant rhabdoid tumor, and oropharyngeal cancer.
24 . The method of claim 23 , wherein the breast cancer is triple-negative breast cancer (TNBC).
25 . The method of any of claims 16 - 24 , wherein the EZH2-mediated cancer is a relapsed cancer.
26 . The method of any of claims 16 - 25 , wherein the EZH2-mediated cancer was refractory to one or more previous treatments.
27 . A method for identifying a bivalent compound which mediates degradation/disruption of EZH2, the method comprising:
providing a bivalent test compound comprising an EZH2 ligand conjugated to a degradation/disruption tag; contacting the bivalent test compound with a cell comprising a ubiquitin ligase and EZH2; determining whether EZH2 levels decrease in the cell; and identifying the bivalent test compound as a bivalent compound which mediates reduction of EZH2 if EZH2 levels decrease in the cell.
28 . The method of claim 27 , wherein the cell is a cancer cell.
29 . The method of claim 28 , wherein the cancer cell is an EZH2-mediated cancer cell.Join the waitlist — get patent alerts
Track US2019255041A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.